Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism.
Levy T, Voeltzke K, Hruby L, Alasad K, Bas Z, Snaebjörnsson M, Marciano R, Scharov K, Planque M, Vriens K, Christen S, Funk CM, Hassiepen C, Kahler A, Heider B, Picard D, Lim JKM, Stefanski A, Bendrin K, Vargas-Toscano A, Kahlert UD, Stühler K, Remke M, Elkabets M, Grünewald TGP, Reichert AS, Fendt SM, Schulze A, Reifenberger G, Rotblat B, Leprivier G. Levy T, et al. Among authors: elkabets m. Nat Commun. 2024 May 14;15(1):4083. doi: 10.1038/s41467-024-48386-y. Nat Commun. 2024. PMID: 38744825 Free PMC article.
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.
Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, Picard D, Qin N, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B. Varon M, et al. Among authors: elkabets m. Int J Cancer. 2019 Dec 15;145(12):3402-3413. doi: 10.1002/ijc.32400. Epub 2019 Jun 12. Int J Cancer. 2019. PMID: 31081944
Synthetic promoters to induce immune-effectors into the tumor microenvironment.
Greenshpan Y, Sharabi O, Ottolenghi A, Cahana A, Kundu K, M Yegodayev K, Elkabets M, Gazit R, Porgador A. Greenshpan Y, et al. Among authors: m yegodayev k, elkabets m. Commun Biol. 2021 Jan 29;4(1):143. doi: 10.1038/s42003-021-01664-7. Commun Biol. 2021. PMID: 33514819 Free PMC article.
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Badarni M, Prasad M, Golden A, Bhattacharya B, Levin L, Yegodayev KM, Dimitstein O, Joshua BZ, Cohen L, Khrameeva E, Kong D, Porgador A, Braiman A, Grandis JR, Rotblat B, Elkabets M. Badarni M, et al. Among authors: elkabets m. Cancers (Basel). 2021 May 7;13(9):2250. doi: 10.3390/cancers13092250. Cancers (Basel). 2021. PMID: 34067117 Free PMC article.
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. Prasad M, et al. Among authors: elkabets m. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917. J Immunother Cancer. 2022. PMID: 35292516 Free PMC article.
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J. Elkabets M, et al. Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747. Sci Transl Med. 2013. PMID: 23903756 Free PMC article.
81 results